Published in Oncogene on October 03, 2016
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A (2006) 5.27
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 4.55
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood (2008) 3.85
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood (2010) 2.61
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev (2012) 2.44
Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med (2010) 2.23
Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol (2001) 2.15
Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood (1999) 2.06
MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene (2009) 1.98
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72
BCL2A1: the underdog in the BCL2 family. Cell Death Differ (2011) 1.56
The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ (2015) 1.38
Multiple gene duplication and expression of mouse bcl-2-related genes, A1. Int Immunol (1998) 1.31
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev (2014) 1.30
Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood (2012) 1.25
Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood (2007) 1.22
Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol (2014) 1.21
Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood (2011) 1.06
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. Int J Cancer (2005) 1.05
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood (2013) 1.02
A1/Bfl-1 in leukocyte development and cell death. Exp Cell Res (2012) 0.97
BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep (2014) 0.96
Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J (2015) 0.90
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood (2010) 0.89
Knockdown of the antiapoptotic Bcl-2 family member A1/Bfl-1 protects mice from anaphylaxis. J Immunol (2014) 0.88
Characterisation of a novel A1-specific monoclonal antibody. Cell Death Dis (2014) 0.84
Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway. J Virol (2006) 0.80
Conditional knockdown of BCL2A1 reveals rate-limiting roles in BCR-dependent B-cell survival. Cell Death Differ (2015) 0.80
BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma. Cell Death Differ (2015) 0.79
The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death Dis (2016) 0.78